Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials, validating biotech’s waning interest Read more →

Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure Read more →

Gilead cancels midstage HIV trial as FDA’s clinical hold remains intact Read more →